Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pieters-van den Bos IC, Vendrik KE, Hoekstra T, Bruno MJ, Diamant M, van Raalte DH, Cahen DL

Diabetes care20 Dec 2016Cited by 21 (Europe PMC)

PMID27998910DOI10.2337/dc16-0836PepBankPUB-27998910

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 2 diabetes, liraglutide did not change exocrine pancreatic function.
In plain wordsIn overweight people with type 2 diabetes, liraglutide did not change how well the pancreas makes digestive fluids.
Peptide
Liraglutide
Outcome
No significant changeExocrine pancreatic function
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
whereas liraglutide did not change exocrine pancreatic function.
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891002
02HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, liraglutide did not increase lipase levels after 12 weeks.
In plain wordsIn overweight people with type 2 diabetes, liraglutide did not raise the pancreatic enzyme lipase after 12 weeks.
Peptide
Liraglutide
Outcome
No significant changeLipase level at 12 weeks
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
Neither therapy increased lipase/amylase levels after 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891003
03HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, liraglutide did not increase amylase levels after 12 weeks.
In plain wordsIn overweight people with type 2 diabetes, liraglutide did not raise the pancreatic enzyme amylase after 12 weeks.
Peptide
Liraglutide
Outcome
No significant changeAmylase level at 12 weeks
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
Neither therapy increased lipase/amylase levels after 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891004
04HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, liraglutide increased lipase levels after 6 weeks.
In plain wordsIn overweight people with type 2 diabetes, liraglutide briefly raised the enzyme lipase after 6 weeks.
Peptide
Liraglutide
Outcome
IncreaseLipase level at 6 weeks
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Measurements
Lipase increase
23.5 U/L
liraglutide, week 6
Source sentences
Summary
liraglutide increased lipase levels after 6 weeks (23.5 U/L [95% CI 2.1-44.8]; P = 0.03)
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891005
05HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, liraglutide increased plasma trypsinogen after 12 weeks.
In plain wordsIn overweight people with type 2 diabetes, liraglutide raised a pancreatic enzyme in blood after 12 weeks.
Peptide
Liraglutide
Outcome
IncreasePlasma trypsinogen at 12 weeks
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Measurements
Plasma trypsinogen increase
34.6 µg/mL
liraglutide, week 12
Source sentences
Summary
Both drugs increased plasma trypsinogen after 12 weeks (liraglutide: 34.6 µg/mL [95% CI 15.1-54.2], P = 0.001; sitagliptin: 23.9 µg/mL [95% CI 4.9-42.9], P = 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891006
06HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, liraglutide did not change pancreatic morphology.
In plain wordsIn overweight people with type 2 diabetes, liraglutide did not change the shape or structure of the pancreas on MRI.
Peptide
Liraglutide
Outcome
No significant changePancreatic morphology on MRI
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
Neither changed pancreatic morphology, although liraglutide tended to increase pancreatic volume (7.7 cm³ [95% CI -1.2 to 16.6]; P = 0.09).
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891007
07HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, liraglutide tended to increase pancreatic volume, but the change was not significant (P = 0.09).
In plain wordsIn overweight people with type 2 diabetes, liraglutide showed a trend to a larger pancreas, but this was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changePancreatic volume
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Measurements
Pancreatic volume change
7.7 cm3
liraglutide
Source sentences
Summary
although liraglutide tended to increase pancreatic volume (7.7 cm³ [95% CI -1.2 to 16.6]; P = 0.09).
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891008
08HumanRandomized controlled trialSafety outcome
In overweight adults with type 2 diabetes, no patient developed pancreatitis in the 12-week trial.
In plain wordsIn overweight people with type 2 diabetes, no one developed pancreatitis during the 12-week trial.
Peptide
Liraglutide
Outcome
No significant changePancreatitis
Study
n = 55
Comparator
Placebo
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.8 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
No patient developed pancreatitis.
2 context sentences(design, population, supporting numbers)
Summary · context
For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included.
Summary · context
Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks.
Report a problemFND-2799891001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.